Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q3 FY19 results · Oct–Dec 2018
Lincoln Pharmaceuticals reported revenue from operations of ₹81.00 crore and net profit of ₹9.45 crore for Q3 FY19 (Oct–Dec 2018), on a standalone basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 81.00 | — | — | 97.95 | −17.3% |
| Other income | 0.53 | — | — | 4.39 | −87.8% |
| Total income | 81.54 | — | — | 102.34 | −20.3% |
| Profit before tax | 11.27 | — | — | 17.96 | −37.2% |
| Net profit for the period | 9.45 | — | — | 14.41 | −34.4% |
| EPS, basic (₹) | 4.73 | — | — | 7.20 | −34.3% |
| Net margin (%) | 11.7 | — | 14.7 |
Standalone
- Filed with BSE
- 12 Feb 2019, 14:57 IST
- Board meeting
- 12 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE